Predict your next investment

HEALTHCARE | Drug Delivery
eurocine.se

See what CB Insights has to offer

Founded Year

1999

Stage

IPO | IPO

Total Raised

$640K

Date of IPO

12/12/2006

About Eurocine

Developer of nasal vaccination technology. The company develops immunological adjuvant and delivery systems designed for use in the administration of vaccines through the mucous membrane in the nose. The adjuvant consists of pharmaceutical formulations based on a combination of endogenous and pharmaceutically-accepted lipids, and has potential applications in the treatment of influenza and HIV.

Eurocine Headquarter Location

Karolinska Science Park Fogdevreten 2

Solna, 171 77,

Sweden

46 8 5088 4595

Latest Eurocine News

Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

Dec 31, 2020

STOCKHOLM, Dec. 31, 2020 /PRNewswire/ -- Eurocine Vaccines AB ("Eurocine Vaccines" or the "Company") has today selected Biovian Oy, Turku, Finland, ("Biovian") as the contract developer for the Company's vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract developer and manufacturer with its own GMP facility, will develop an industrial manufacturing method as well as manufacture study products for Eurocine Vaccines' future studies, such as toxicological and clinical studies. The collaboration for the development of a manufacturing method and preparations to produce the first batches will begin directly in the new year 2021 under the agreement signed today and includes activities at a total cost of appr. SEK 9.5 million (EUR 0.94 million). The costs fall within the Company's budget for the chlamydia project. The work is within one of the prioritized areas that constitute Eurocine Vaccines' key competencies. The collaboration signed today with Biovian covers activities initially lasting until November 2021. The mutual intention is to continue the collaboration until the project is completed. CEO Hans Arwidsson comments "Both we and Biovian are looking forward to the collaboration and the mutual knowledge transfer within biological pharmaceutical production, which is a highly intense area in the development of new pharmaceuticals. The selection of Biovian means that we can conduct our activities with continuity, since they also have their own GMP facility for the manufacture of products for clinical studies." This information is such information that Eurocine Vaccines AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person set out above, for publication on 30 December 2020. CONTACT:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Eurocine Patents

Eurocine has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/17/2013

7/20/2021

Vaccines, Influenza, Vaccination, Virology, Animal virology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/17/2013

00/00/0000

00/00/0000

Grant Date

7/20/2021

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Vaccines, Influenza, Vaccination, Virology, Animal virology

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.